key: cord-0831759-9ud32cvb
authors: Murrell, A. E.; Eyoh, E.; Shaffer, J. G.; Dietrich, M. L.; Trinh, I. V.; yockachonis, T. J.; Bai, S.; Zheng, C. Y.; Mayne, C. V.; Cabrera, S. E.; Aviles-Amaro, A.; Stone, A. E.; Rambaran, S.; Chandra, S.; Elliott, D. H.; Smira, A. R.; Harris, S. N.; Olson, K. E.; Bilton, S. J.; Gabriel, M. J.; Falgout, N. D.; Engel, E. J.; Prystowsky, A. D.; Ning, B.; Hu, T.; Kolls, J. K.; Landry, S. J.; Drury, S. S.; Schieffelin, J. S.; Zwezdaryk, K. J.; Robinson, J. E.; Browyn, G. M.; Norton, E. B.
title: Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and Age.
date: 2022-04-22
journal: nan
DOI: 10.1101/2022.04.22.22274032
sha: 01de0ef4eb345d89a600b7a3d40df1d79b95b738
doc_id: 831759
cord_uid: 9ud32cvb

SARS-CoV-2 infection causes a spectrum of clinical outcomes and diverse memory responses. Population studies indicate that viral neutralizing antibody responses are protective, but do not always develop post-infection. Other antiviral antibody effector functions, T-cell responses, or immunity to seasonal coronaviruses (OC43, 229E) have been implicated but not defined in all ages. Here, we identify that children and adult subjects generate polyfunctional antibodies to the spike protein after asymptomatic infection or mild disease, with some subjects developing cellular responses without seroconversion. Diversity in immunity was explained by two clusters distinguished by CD4+ T-cell cytokines, age, and antibodies to seasonal coronaviruses. Post-vaccination neutralizing responses were predicted by specific post-infection immune measures, including IL-2, spike-IgA, OC43-IgG1, 229E-IgM. We confirm a key role for CD4+ T cell cytokines in functionality of anti-spike antibodies, and show that antibody diversity is impacted by age, Th/Th2 cytokine biases, and antibody isotypes to SARS-CoV-2 and seasonal coronaviruses.

). Importantly, none of the participants had been hospitalized for infection, 106 although ten subjects reported visiting the emergency room for their illness.

SARS-CoV-2 infection in 67 subjects (74%) was confirmed either by a PCR test (n=42), SARS-108 CoV-2 spike or nucleoprotein specific IgG by ELISA and Luminex testing (54 and 32 subjects, 109 respectively) or viral RNA detection in plasma (n=11) by a sensitive CRISPR assay [33, 34] . The BMI, but not sex, race, or household. These analyses demonstrate that medical co-morbidities 125 observed in hospitalized COVID-19 patients were also relevant in this non-hospitalized cohort.

binding domain (RBD) , and the nucleoprotein [N] ) and seasonal coronaviruses (OC43, HKU1, 132 229E, and NL63) spike proteins.

As expected, SARS-CoV-2 specific antibodies were significantly elevated in subjects with SARS-

CoV-2 infection compared with uninfected individuals (Figure 2A, Figure S1 ). No significant 135 differences were observed between infection groups with respect to the levels of antibodies 136 against the seasonal coronaviruses. Sampling times post-infection differed across the cohort.

While the time between sampling and infection did not correlate with increasing/decreasing IgG1 138 across individuals, elevated levels of IgG4 were observed in samples collected further from 139 infection, suggesting temporal development of virus-specific IgG4 ( Figure 2B) . A subset of 140 subjects (n=18) returned for follow-up visits six months after visit 1 (and before any vaccination).

In these subjects, spike-and N-specific IgG responses were relatively stable over time ( Figure   142 S2). However, a small but significant increase in spike-specific IgA1 was observed in the follow- 

To determine cellular immunity post-infection, we evaluated stored PBMCs from all subjects for 172 CD4+ and CD8+ T-cell reactivity and cytokine secretion in response to SARS-CoV-2 spike 173 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 protein, nucleoprotein, or matrix peptide pools after in vitro stimulation for 24h. Activation was 174 assessed by flow cytometry of stimulated versus non-stimulated PBMC cultures by gating for 175 CD134-high expression on CD4+ T cells or CD69 expression on CD8+ T-cells as a modified 176 activation-induced marker expression (AIM) (Figure S4A,B) . As previously reported in SARS-

CoV-2 infected subjects [4, 24, 26] , significant CD4+ and CD8+ T cell AIM to spike protein or 178 peptide were observed compared to non-infected subjects ( Figure 3A ). CD4+ T cell AIM 179 responses were stable over 6 months in the individuals who returned for a follow-up visit ( Figure   180 S2E-F) and were not correlated with the day of sample collection ( Figure S4F ). Interestingly, a 181 subset of infected subjects had detectable T-cell responses with no observable antibody 182 responses ( Figure S3A,B) , indicating that these subjects exhibit cellular sensitization without 

Induced cytokine secretion was highly correlated among almost all restimulation antigens 188 including spike protein, spike peptide, N peptide, or matrix peptide ( Figure S5 ). As anticipated [4, 189 24-28], Th1-biasing IL-2 and IFNγ secretion was observed in response to spike and nucleoprotein, 

IL-17, the latter of which was highly correlated to IL-2 responses ( Figure S5 ). Significant changes 197 in parameters such as IL-4, IL-10, Granzyme B, and perforin were not observed for any stimulation 198 condition related to infection status ( Figure S4E ).

As T-cell and cytokine secretion can impact the generation of antibodies and have been 200 implicated in pre-existing immunity to seasonal coronaviruses, we correlated cellular immunity 201 measures with SARS-CoV-2 and seasonal coronavirus IgG antibodies ( Figure 3G ). CD4+ T-cell 202 AIM, IL-2 secretion, and Th1-associated cytokines were significantly correlated to plasma levels 203 of SARS-CoV-2 spike, RBD, and N IgG. Spike peptide pools but not protein for AIM significantly 204 correlated to OC43 and NL63 IgG. In contrast, symptom score was highly associated with TNFα, 205 IL-4, and IL-10, even though these cytokines individually were not different between infected and 206 non-infected subjects, suggesting that these cytokines track with disease severity.

Age drives immunity to SARS-CoV-2 infection.

The diversity of the study cohort (Table 1 ) allowed us to evaluate the relationship between age, 209 sex, and SARS-CoV-2 immunity. In infected subjects, higher levels of chronic conditions and 210 SARS-CoV-2 symptom scores were associated with increasing age ( Figure 4A ) and correlated 211 with increased levels of spike-specific IgG1, neutralizing antibodies, IL-2, CD8+ T-cell activation, 212 and the related antiviral cytokines perforin and Granzyme B (Figure 4B-D) . Minimal changes in 213 seasonal coronavirus IgG were observed with age ( Figure 4B ). Sex had no significant impact on 214 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 these measures ( Figure 4B) ; however, both sex and age were significantly related to IgM 215 antibody levels to Spike and RBD ( Figure 4B ).

Immunity in infected subjects can be separated into two groups based on Th1 or Th2 217 biased immune responses and antibody isotypes (IgM/IgG1 or IgG2/IgG4).

To dissect the relationship between cellular and serologic immunity with all disease parameters 219 and demographic information, we used t-SNE and UMAP data visualizations for immune 220 response to SARS-CoV-2 proteins or peptides. These analyses resulted in two distinct 221 populations (e.g., t-SNE 1 and t-SNE 2) verified by k-means clustering ( Figure 5A, Figure S6A ).

These populations were compared for all measures of SARS-CoV-2 immunity, demographic, 223 infection, or other seasonal coronavirus variables (Table S2) . Across the demographic and 224 disease variables, older age was associated with population 1, and minor symptoms or specific Table S2 ). Neutralization 235 in this population did not correlate to Th1 cytokines but was negatively correlated with IL-4 ( Figure   236 5D, Figure S6E ). In addition, perforin and ADNK activities were higher, suggesting population 2 237 may have higher NK or NKT cell activity. These data indicate that within this non-hospitalized 238 cohort, SARS-CoV-2 immunity can diverge into Th1-biased immunity (observed in population 1) 239 or Th2-biased immunity (observed in population 2), likely related to patient age. It is possible that 240 lingering viral infection or antigen also contribute to population differences, as this showed up in 241 both UMAP and correlation analyses. (Figure 5E, Figure S6B ).

These observations were complemented with a network analysis of immune parameters in SARS-

CoV-2 infected subjects, which demonstrated that neutralizing and functional antibody levels were 244 associated with CD4+ T cell help (indicated by CD4+ AIM and induction of Th1 cytokines),

whereas T cell production of IL-4 and IL-10 were negatively associated with antiviral antibody 246 functions ( Figure 5E ). The univariate correlation analysis between these T cell parameters, 

Together, these data suggest that the balance of Th1/Th2 CD4+ T-cell responses played a key 254 role in developing qualitative SARS-CoV-2 antibody responses and points to a potential role for

IgM, but not IgG1, responses against seasonal coronaviruses in promoting Th1 immunity.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Post-vaccination responses are predicted by Th1 immunity.

With ongoing vaccinations, it is also unclear how prior infection will shape long-term and vaccine- 

To understand how prior SARS-CoV-2 immunity resulting from infection impacted vaccine-262 mediated immunity, we obtained follow-up samples from a subset of infected subjects who 263 received SARS-CoV-2 vaccine (n=32; age 16-79 years old (mean 43) and 63% female). These 

For samples collected after 3 months, older age, type of vaccine received, B-cell activating factor 296 (BAFF), and lower levels of antibodies against the seasonal coronaviruses, including IgG1 OC43,

IgM 229E, and IgA1 229E tracked with higher neutralizing antibodies ( Figure 6E, Figure S7B ),

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10. 1101 suggesting that durable vaccine-mediated immunity is also shaped by prior SARS-CoV-2 and 299 seasonal coronavirus immunity and age.

Finally, a comparison of the post-vaccination neutralizing antibody titers between subjects in 301 population 1 (Th1 biased immunity) and population 2 (Th2 biased immunity) showed a trend 302 towards higher neutralizing antibodies in population one post-vaccination ( Figure 6F ). This finding CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 , it is possible that IgM levels in our cohort could be more than a temporal antibody 340 maturation response and should be studied further.

The combined induction of functional cellular and humoral immunity is likely a key factor in long-342 term immunity. We observed a much higher correlation of antibody measures to CD4+ T-cells 343 and cytokines than to CD8+ T-cells (Figure 3, 5) , consistent with other reports on humoral 344 memory [45, 46] . However, CD8+ T cell activation was also significantly detected and altered by 345 age (Figure 3, Figure 4) , and CD8 activation to spike peptide pools seemed to limit post-346 vaccination neutralization responses (Figure 6 ). This finding may reflect that specific CD8+ T-cell 

Antibody-dependent, complement-mediated delivery of antigen to dendritic cells has been shown 356 to enhance production of neutralizing antibodies [43] , thus in addition to having higher numbers 357 of memory B cells, one potential hypothesis is that enhanced delivery of vaccine antigens to 358 antigen presenting cells by existing SARS-CoV-2 specific antibodies helps drive higher 359 neutralizing antibody levels.

The development of Th1-biased responses in subjects within cluster 1 tracked with overall older 361 age, but not with symptom severity or SARS-CoV-2 infection. Intriguingly, subjects in cluster 2 362 reported experiencing more minor symptoms (e.g., nausea, runny nose (coryza), nasal 363 congestion, cough, and headache) or specific symptoms (e.g., loss of taste) and had elevated 364 levels of virus-specific IgG2 and IgG4 compared with subjects in cluster 1. While virus-specific 365 IgG1 and IgG3 were not different between the two clusters, antibody functionality and 366 neutralization were significantly different, highlighting that antibody features beyond IgG 367 subclasses may further drive differences in antiviral functionality between the two groups.

Antibody glycosylation can further modify the induction of innate immune effector functions. While 369 we did not evaluate antibody glycosylation in this study, several studies have found that severe 

This study also revealed an association with Th2 cytokines, including IL-4, IL-13, and IL-10, which 374 inversely correlated to neutralization after infection but only weakly to post-vaccination 375 neutralization (Figure 2, Figure 6 , Figure S7B) . A Th2 profile has also been implicated in severe 376 COVID disease [31], though these patients were not in our study population. IL-10 was strongly 377 correlated with IgA response to spike in our cohort, which was a key factor in lower post- CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 tissue and blood and correlates to IgG [53, 54] . mRNA vaccination is known for boosting high 383 levels of neutralizing serum antibodies but not mucosal IgA responses even in previously infected 384 individuals [55] . However, these findings suggest that IgA responses play a negative role in post-385 vaccination neutralizing antibody magnitude and duration and may be the result of IL-10 secretion 386 that that should be explored further. Taken together, this data indicate a key role for cellular 387 immunity and cytokine biases in infection outcomes and post-vaccination responses.

Whether prior exposure to seasonal coronaviruses shapes SARS-CoV-2 specific immunity has 389 been a key question since the beginning of the pandemic. Pre-pandemic pediatric samples have (Figure 2, Figure S1 ), there were significant correlations 397 between antibodies to SARS-CoV-2 spike, and nucleoprotein and those to spike proteins of 398 seasonal coronaviruses ( Figure 2F ). Age did not correlate with the magnitude of these seasonal 399 coronavirus IgG antibodies (Figure 4) . We also observed that OC43 and NL63 IgG levels 400 correlated with activation of T cells with spike peptide pools, but not protein (Figure 3) 

cytokines between spike or peptide pools were highly correlated (Figure S5) , indicating T-cell 423 production. Also, high expression of IL-2 has been routinely observed from CD4+ T-cell and not 424 CD8+ T-cells after SARS-CoV-2 infection [28, 38] . In this study, IL-17A secretion was closely 425 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

Our study used samples collected from subjects only shortly after the pandemic which will be 432 difficult to perform as COVID subsides and vaccination rates increase in the general population.

Our findings indicate that SARS-CoV-2 specific humoral responses and functions are likely 

Declaration of Interests. The authors declare no competing interests. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Symptoms and illness severity scores 627 A general symptom score was calculated according to the September 2021 CDC classification 628 (prior to circulation of the Omicron variant). Two points were given according to each major 629 symptom: cough, shortness of breath, difficulty breathing, loss of smell, and loss of taste. One-630 half of a point was given for each minor symptom: fever, runny nose, nasal congestion, sore 631 throat, diarrhea, vomiting, fatigue, muscle aches, chills, nausea, and headache. Total symptom 632 score was calculated as the sum of the major and minor scores.

Because illness severity is not necessarily measurable by the point-based approach used for the 635 general symptom score, it was calculated according to clinical manifestations thresholds based 636 on lung involvement and impairments, as detailed in Baj et al. (2020, [63] ). Specifically, the 637 severity score was defined as severe (abdominal pain, shortness of breath, difficulty breathing, 638 chest pain, vomiting, nausea, diarrhea); moderate (fever, cough, runny nose, fatigue, muscle 639 aches, loss of smell, headache, sore throat, loss of taste, nasal congestion, chills, repeated chills, 640 hair loss, toes); and asymptomatic (no reported symptoms). Hair loss was considered to be 641 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 typically associated with long-term COVID-19 symptoms and thus was not considered as an 642 acute, severe symptom.

Age was based on self-reported birth date at study enrollment. Body mass index (BMI) was 646 defined as weight in kilograms divided by height in meters squared. For adults, BMI was 647 calculated as: as <18.5 (underweight), 18.5-30 (normal), and >30 (overweight/obese). For 648 children (aged under 18 years), BMI was calculated as <5 th percentile (underweight), between the 649 5 th and 95 th percentile (normal), and greater than the 95 th percentile (overweight/obese). CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Immunology) [66, 67] ). Stable expression was maintained via blasticidin selection in stably 686 transfected 293F cells. Recombinant protein was purified from clarified culture medium by affinity 687 chromatography on Streptactin X affinity columns. RBD (aa321-535) was similarly expressed in 688 the phCMV plasmid and purified on Streptactin X affinity columns.

A DNA fragment encoding SARS CoV-2 N protein, including its natural leader sequence was 

Similar ELISAs were run with purified RBD and N protein-coated in wells. For the RBD ELISA, 715 protein was coated at 500 ng/ml in 100 ul of 100 mM sodium bicarbonate. For the N protein ELISA, 716 protein was coated at 2 ug/ml. Otherwise, the ELISA procedure was the same as for the spike 717 protein ELISA. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

After 66-72 hours of incubation, the medium was removed by gentle aspiration. Then, 100 ul of 750 1:6 dilution of Promega BriteGlo in Glo lysis buffer was added to the wells with mixing. Plates 751 were incubated for 7 minutes at room temperature, after which luminescence was measured in a

Biotek Synergy H1 Luminometer. Neutralization titers were defined as the serum dilution (ID50) 753 at which relative luminescence units (RLU) were reduced by 50% compared to virus control wells 

Recombinant SARS-CoV-2 spike was coated onto MaxiSorp 96-well plates (Thermo Scientific 768 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 antibodies were removed by centrifugation before adding THP-1 cells at 2.5x10 4 cells/well. Cells 799 were fixed with 4% paraformaldehyde and analyzed by flow cytometry for uptake of fluorescent 800 beads on a Cytek Aurora spectral flow cytometer. A phagocytic score was determined as 801 described above, and the areas under the curve for the three dilutions were calculated.

Protocol was adapted from [74] . Recombinant SARS-CoV-2 spike-coated beads were generated 805 as described for ADNP. Serum samples were diluted in culture medium 1:10 and incubated with 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Cytokine test kits were used to measure cytokine levels in supernatant fluids from restimulated 838 PBMC cultures according to manufacturers' protocol. Kit types included Bio-plex Pro Human 839 Cytokine 17-plex (Biorad) or custom human (Biorad Bio-plex IFN-y, IL-2, IL-5, IL-6, TNFα; 

Cat# 442404) at 300 ng/well at 4°C overnight. Wells were washed with PBS and blocked with 5%

Serum samples diluted 1:50 in PBS were added to the wells and incubated for 2 h at 37 °C

Unbound antibodies were removed by washing wells with PBS. NK92 cells in complete alphaMEM 771 culture medium were added at 5 x 10 4 cells/well in the presence of 4 µg/ml brefeldin A (Biolegend 772 Cat# 420601), 5 µg/ml GolgiStop (BD Biosciences Cat# 554724)

Biolegend Cat# 328618) for 5 hours at 37°C. Cells were stained 774 for surface expression of CD16 (Clone 3G8 Pacific Blue, Biolegend Cat# 302032) and CD56 775 (clone 5.1H11 AlexaFluor488 Biolegend, Cat# 362518

Biolegend Cat# 421002) according to the manufacturer's instructions and stained for 777 intracellular IFNg (Clone B27 PE

Cells were analyzed on a Cytek Aurora spectral flow cytometer

Antibody-dependent neutrophil phagocytosis (ADNP)

Serum samples diluted 1:100 in 783 culture medium were incubated with spike-coated beads for 2h at 37°C. Freshly isolated white 784 blood cells from human donor peripheral blood (5x104 cells/well) were added to wells and 785 incubated for 1 hour at 37°C. Cells were stained for CD66b (Clone G10F5; Biolegend)

A phagocytic score was 789 determined using the following formula: (percentage of bead+ cells)*(geometric mean fluorescent 790 intensity (gMFI) of red bead+ cells

Antibody-dependent cellular phagocytosis by human monocytes (ADCP)

Protocol was adapted from

L-glutamine, and b-795 mercaptoethanol. Recombinant SARS-CoV-2 spike-coated beads were generated as described 796 for ADNP. Serum samples were diluted in a five-fold dilution curve in THP-1 culture medium 797 (1:2500, 1:12500, 1:62500) and incubated with spike-coated beads for 2 h at 37 °C

Protective immunity after recovery from SARS-CoV-2 878 infection

CD8(+) T cells contribute to survival in patients with COVID-19 and 880 hematologic cancer

COVID-19 infection in 10 common variable immunodeficiency patients in 882 New York City

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with 884 COVID-19 Disease and Unexposed Individuals

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and 886 uninfected controls

Adaptive immune determinants of viral clearance and protection in 888 mouse models of SARS-CoV-2. Sci Immunol

Correlates of protection against SARS-CoV-2 in rhesus macaques. 890 Nature

Association of Age With SARS-CoV-2 Antibody Response

Aging, Immunity, and COVID-19: How Age Influences the Host Immune 894 Response to Coronavirus Infections? Front Physiol

Immunology of SARS-CoV-2 infection in 898 children

SARS-CoV-2 specific T cell responses are lower in children and increase 900 with age and time after infection

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in 902

Acute COVID-19 and Associations with Age and Disease Severity

Distinct antibody responses to SARS-CoV-2 in children and adults 905 across the COVID-19 clinical spectrum

Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable 907 neutralizing antibody responses in children and adolescents

Sex, age, and hospitalization drive antibody responses in a COVID-19 909 convalescent plasma donor population

Clinical and immunological assessment of asymptomatic SARS-CoV-2 911 infections

SARS-CoV-2 neutralizing antibody responses are more robust in patients 913 with severe disease

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. 915

Neutralising antibody titres as predictors of protection against SARS-917

CoV-2 variants and the impact of boosting: a meta-analysis

Neutralizing antibody levels are highly predictive of immune protection 920 from symptomatic SARS-CoV-2 infection

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 924 Mortality

Highly functional virus-specific cellular immune response in 926 asymptomatic SARS-CoV-2 infection

T-cell immunity of SARS-CoV: Implications for vaccine development against 928 MERS-CoV

The T cell immune response against SARS-CoV-2

SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent 932 patients for 10 months with successful development of stem cell-like memory T cells. Nat 933 Commun

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-935 2 in UK convalescent individuals following COVID-19

T-cell responses to MERS coronavirus infection in people with 938 occupational exposure to dromedary camels in Nigeria: an observational cohort study. 939 Lancet Infect Dis

Longitudinal analysis reveals that delayed bystander CD8+ T cell 941 activation and early immune pathology distinguish severe COVID-19 from mild disease. 942 Immunity

Integrated longitudinal immunophenotypic, transcriptional and 944 repertoire analyses delineate immune responses in COVID-19 patients

Mild SARS-CoV-2 infection in rhesus macaques is associated with viral 947 control prior to antigen-specific T cell responses in tissues

Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-950 2 infection

Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 952 diagnosis

Systemic IL-15, IFN-gamma, and IP-10/CXCL10 signature 954 associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine 955 recipients

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 957 variants

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 959

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild 961 COVID-19

Over 1-year duration and age difference of SARS-CoV-2 antibodies in 963 convalescent COVID-19 patients

Neutralizing antibody titres in SARS-CoV-2 infections

SARS-CoV-2 infection induces sustained humoral immune responses in 967 convalescent patients following symptomatic COVID-19

Correlation between viral RNA shedding and serum antibodies in individuals 970 with coronavirus disease 2019

Antigen-specific antibody Fc glycosylation enhances humoral immunity 972 via the recruitment of complement

Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival, 974 and humoral immune responses

Memory B cells targeting SARS-CoV-2 spike protein and their dependence 976 on CD4(+) T cell help

Humoral and circulating follicular helper T cell responses in recovered 978 patients with COVID-19

SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 980 individuals

Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA 982 vaccine

Afucosylated IgG characterizes enveloped viral responses and 984 correlates with COVID-19 severity

High titers and low fucosylation of early human anti-SARS-CoV-2 IgG 986 promote inflammation by alveolar macrophages

Early non-neutralizing, afucosylated antibody responses are 988 associated with COVID-19 severity

Proinflammatory IgG Fc structures in patients with severe COVID-990

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients

Systems serology detects functionally distinct coronavirus antibody 998 features in children and elderly

Boosting of cross-reactive antibodies to endemic coronaviruses by 1000 SARS-CoV-2 infection but not vaccination with stabilized spike. Elife, 2022. 11

Early cross-coronavirus reactive signatures of humoral immunity 1002 against COVID-19

Pre-existing humoral immunity to human common cold coronaviruses 1004 negatively impacts the protective SARS-CoV-2 antibody response

Comprehensive analysis of T cell immunodominance and 1007 immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

Rapid induction of antigen-specific CD4(+) T cells is associated with 1010 coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: 1016 The Current State of Knowledge

Isolation and preservation of peripheral blood mononuclear cells for 1018 analysis of islet antigen-reactive T cell responses: position statement of the

Workshop Committee of the Immunology of Diabetes Society

Optimal blood mononuclear cell isolation procedures for gamma 1022 interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: 1025 A global consortium study

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug 1029 Targets and Potential Drug-Repurposing. bioRxiv

SARS-CoV-2 spike-protein D614G mutation increases virion spike density 1031 and infectivity

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to 1033 Neutralization

Efficient transfer, integration, and sustained long-term expression of the 1035 transgene in adult rat brains injected with a lentiviral vector

A versatile high-throughput assay to characterize antibody-mediated 1038 neutrophil phagocytosis

A robust, high-throughput assay to determine the phagocytic 1040 activity of clinical antibody samples

A high-throughput, bead-based, antigen-specific assay to assess the 1042 ability of antibodies to induce complement activation

Multiparameter Conventional Flow Cytometry

Increased fat cell size: a major phenotype of subcutaneous white 1047 adipose tissue in non-obese individuals with type 2 diabetes

Data visualization with t-SNE and UMAP